Search

Your search keyword '"Koller, Paul"' showing total 55 results

Search Constraints

Start Over You searched for: Author "Koller, Paul" Remove constraint Author: "Koller, Paul" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
55 results on '"Koller, Paul"'

Search Results

1. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation

2. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab

3. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

4. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

6. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

10. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies

12. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

13. Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

14. CML-400 Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

15. Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

17. Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

18. Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity

19. Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

20. Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

21. Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

22. Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience

27. POSTER: AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage

28. 569 - Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients 75 Years and Older: Another Age Barrier Crossed?

29. 219 - Fludarabine and Melphalan (FM) with Post-Transplant Cyclophosphamide (PTCy) for Peripheral Blood Stem Cell (PBSC) Allogeneic Hematopoietic Cell Transplant (HCT) in Patients with Hematologic Malignancies

30. 133 - Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

31. 146 - Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

32. 145 - Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with Measurable Residual Disease and the Impact of Conditioning Regimen and Graft-Versus-Host Disease Prophylaxis Intensity: A Single Center Retrospective Analysis

33. 127 - Outcomes of MDS Patients with and without Spliceosome Mutations Undergoing Allogeneic Hematopoietic Cell Transplantation

34. Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

36. Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

37. Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

38. Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)

39. Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy

40. Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

41. Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

42. Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

43. 316 - Adverse Impact of Renal Impairment on Outcome of Patients Undergoing Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation

44. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

46. 147 - Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

48. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression

Catalog

Books, media, physical & digital resources